ORIENT EUROPHARMA CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.2 TWD | +2.30% |
|
+3.43% | +8.48% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,520 | 4,823 | 4,173 | 3,153 | 3,140 | 3,374 |
| Enterprise Value (EV) 1 | 4,027 | 5,158 | 4,247 | 5,334 | 6,293 | 6,114 |
| P/E ratio | 18.4 x | 19.6 x | 21 x | 26.3 x | -10.1 x | 23.4 x |
| Yield | 3.45% | 3.24% | 3.12% | 2.34% | - | 2.57% |
| Capitalization / Revenue | 0.82 x | 0.79 x | 0.78 x | 0.66 x | 0.66 x | 0.73 x |
| EV / Revenue | 0.73 x | 0.85 x | 0.79 x | 1.12 x | 1.33 x | 1.33 x |
| EV / EBITDA | 8.77 x | 10.7 x | 15.2 x | 92.2 x | 220 x | 25.9 x |
| EV / FCF | -452 x | -277 x | 14.3 x | -3.66 x | -9.13 x | 41.5 x |
| FCF Yield | -0.22% | -0.36% | 6.99% | -27.3% | -10.9% | 2.41% |
| Price to Book | 1.38 x | 1.51 x | 1.3 x | 1.07 x | 1.07 x | 0.96 x |
| Nbr of stocks (in thousands) | 86,747 | 86,747 | 86,747 | 86,747 | 86,747 | 86,747 |
| Reference price 2 | 52.10 | 55.60 | 48.10 | 36.35 | 36.20 | 38.90 |
| Announcement Date | 3/13/19 | 3/2/20 | 3/2/21 | 3/2/22 | 3/7/23 | 3/1/24 |
1TWD in Million2TWD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 5,510 | 6,093 | 5,384 | 4,767 | 4,730 | 4,592 |
| EBITDA 1 | 459.3 | 484 | 278.7 | 57.87 | 28.61 | 235.8 |
| EBIT 1 | 355.3 | 336.4 | 117.7 | -98.15 | -149.5 | 70.61 |
| Operating Margin | 6.45% | 5.52% | 2.19% | -2.06% | -3.16% | 1.54% |
| Earnings before Tax (EBT) 1 | 369.7 | 365 | 249.9 | 84.77 | -328.1 | 256.3 |
| Net income 1 | 246.7 | 247.7 | 199.3 | 120.2 | -310.8 | 143.9 |
| Net margin | 4.48% | 4.06% | 3.7% | 2.52% | -6.57% | 3.13% |
| EPS 2 | 2.830 | 2.840 | 2.290 | 1.380 | -3.583 | 1.659 |
| Free Cash Flow 1 | -8.919 | -18.61 | 297 | -1,457 | -689 | 147.3 |
| FCF margin | -0.16% | -0.31% | 5.52% | -30.57% | -14.56% | 3.21% |
| FCF Conversion (EBITDA) | - | - | 106.57% | - | - | 62.5% |
| FCF Conversion (Net income) | - | - | 149.01% | - | - | 102.36% |
| Dividend per Share 2 | 1.800 | 1.800 | 1.500 | 0.8500 | - | 1.000 |
| Announcement Date | 3/13/19 | 3/2/20 | 3/2/21 | 3/2/22 | 3/7/23 | 3/1/24 |
1TWD in Million2TWD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | 335 | 74.4 | 2,181 | 3,153 | 2,739 |
| Net Cash position 1 | 492 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | 0.6922 x | 0.2668 x | 37.69 x | 110.2 x | 11.62 x |
| Free Cash Flow 1 | -8.92 | -18.6 | 297 | -1,457 | -689 | 147 |
| ROE (net income / shareholders' equity) | 3.58% | 3.44% | 2.77% | 2.02% | -8.57% | 4.45% |
| ROA (Net income/ Total Assets) | 3.2% | 2.78% | 0.92% | -0.7% | -0.94% | 0.42% |
| Assets 1 | 7,718 | 8,901 | 21,718 | -17,204 | 32,980 | 34,643 |
| Book Value Per Share 2 | 37.80 | 36.80 | 37.00 | 33.90 | 33.80 | 40.50 |
| Cash Flow per Share 2 | 20.20 | 20.20 | 24.50 | 22.60 | 20.80 | 20.00 |
| Capex 1 | 202 | 128 | 233 | 1,563 | 639 | 99.4 |
| Capex / Sales | 3.66% | 2.11% | 4.32% | 32.78% | 13.51% | 2.16% |
| Announcement Date | 3/13/19 | 3/2/20 | 3/2/21 | 3/2/22 | 3/7/23 | 3/1/24 |
1TWD in Million2TWD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| +8.48% | 112M | |
| +8.20% | 7.78B | |
| +0.34% | 7.38B | |
| +10.20% | 6.52B | |
| -8.10% | 3.67B | |
| -14.57% | 1.17B | |
| +8.34% | 934M | |
| -42.27% | 879M | |
| -18.90% | 836M | |
| -16.45% | 802M |
- Stock Market
- Equities
- 4120 Stock
- Financials Orient EuroPharma Co., Ltd.
